FDA Alert about Efficacy and Potention Safety using Atezolizumab in combination with paclitaxel in Breast Cancer

Date of Article Published: September 8, 2020

In these Article FDA gives conclusion to the Oncology clinical investigators, health care professional and patient with previously untreated inoperable locally advanced triple negative breast cancer showed that the drug combination of Atezolizumab and paclitaxel do not work to treat diseases.

Atezolizumab in combination with the paclitaxel is not approved by the FDAa for the treatment of the breast cancer. However these combination can only be used when  tumor is metastatic triple negative breast cancer and PD-L1 positive as determined by FDA approved test. 

DRUGS USED IN BREAST CANCER: 

• Abemacicilib
• Abraxan(Paclitaxel albumin stabilized nanoparticel)
• Ado-Trastuzumab 
• Alpelicib
• Aredia
• Arimidex(Anastrazole)

These are the general drugs used in the Most common types of breast cancer, as there are many types of  breast cancer observed in female the drugs also varies according to the types of breast cancer.